Want to see ABOS full AI Analyst Report?
ABOS Stock Chart & Stats
$3.10
-$0.04(-1.84%)
At close: 4:00 PM EDT
$3.10
-$0.04(-1.84%)
Day’s Range― - ―
52-Week Range$1.50 - $3.60
Previous CloseN/A
Volume226.14K
Average Volume (3M)538.86K
Market Cap
$128.00M
Enterprise Value$114.36M
Total Cash (Recent Filing)$110.20M
Total Debt (Recent Filing)$31.57M
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Oct 26, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding72,317,280
10 Day Avg. Volume537,311
30 Day Avg. Volume538,862
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.49K
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$7.00Price Target Upside125.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase II Clinical CatalystThe late-2026 ALTITUDE-AD readout is a material value-creation milestone because it can establish whether sabirnetug’s oligomer-targeting approach produces clinical benefit. Positive efficacy and safety data could support advancement toward Phase 3 and improve partnering prospects.
Promising Brain-delivery PipelineThe EBD program offers a potentially differentiated platform beyond the lead antibody, with substantially improved brain exposure demonstrated preclinically while preserving oligomer selectivity. If translated clinically, this could expand Acumen’s pipeline and strengthen its competitive position.
Clinical And Commercial PositioningA strategy to advance sabirnetug with a partner could provide development expertise, capital and broader commercialization capabilities if the Phase 2 data are successful. The focus on soluble oligomers and safety differentiation also gives the program a defined positioning within Alzheimer’s treatment.
Bears Say
Pre-revenue Operating ModelAcumen has no commercial revenue base to offset research spending, while substantial losses indicate that operating performance depends on continued external financing. Until a candidate is approved and commercialized, the company cannot fund its cost structure through recurring product sales.
Limited Cash Runway And Funding RiskThe expected runway into early 2027 may not cover all planned development needs, including the EBD program’s mid-2027 IND target. Additional financing could therefore be needed, creating dilution or funding pressure before important clinical and regulatory milestones are reached.
EBD Program Remains PreclinicalAlthough the preclinical exposure results are encouraging, the EBD franchise still faces important development decisions before human testing begins. Lead selection, trial design, anemia-risk mitigation and clinical transition strategy could affect timelines, costs and the probability of successful translation.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $1.50 and its highest was $3.60 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $128.00M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Oct 26, 2026 which is in 5 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.359 by -$0.091.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -0.39.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 72,317,280 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.359. Following the earnings report the stock price went up 1.619%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (125.81% Upside)
$7.00 (125.81% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.80%
12-Months-Change
Fundamentals
Return on Equity
-136.27%
Trailing 12-Months
Asset Growth
-32.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
ABOS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful scientific and programmatic progress: a high-impact Phase II readout expected late 2026, strong Phase I target engagement, and a differentiated EBD program with compelling non-human primate brain exposures (up to 40x). Financially, the company is managing costs (R&D down versus prior year; G&A stable) but has a finite cash runway (approximately into early 2027) and reported a sizable quarterly net loss, which creates funding risk ahead of mid-2027 IND plans. Operational and design uncertainties (powering details for two-dose analysis, selection of EBD clinical lead, clinical start strategy) were noted but do not outweigh the near-term scientific catalysts and preclinical wins. Overall the tone is cautiously optimistic pending the upcoming ALTITUDE-AD topline.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$7.00
▲(125.81% Upside)
Technical Analysis
Ownership Overview
32.72% Insiders
5.71% Mutual Funds
0.02% Other Institutional Investors
55.69% Public Companies and
Individual Investors